S
Steven M. Haffner
Researcher at University of Texas Health Science Center at San Antonio
Publications - 8
Citations - 3771
Steven M. Haffner is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 8, co-authored 8 publications receiving 3581 citations.
Papers
More filters
Journal ArticleDOI
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Steven E. Kahn,Steven M. Haffner,Heise Ma,William H. Herman,Rury R. Holman,Nigel P. Jones,Barbara G. Kravitz,John M. Lachin,O'Neill Mc,Bernard Zinman,Giancarlo Viberti +10 more
TL;DR: The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes.
Journal ArticleDOI
A Diabetes Outcome Progression Trial (ADOPT) An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes
Giancarlo Viberti,Steven E. Kahn,Douglas A. Greene,William H. Herman,Bernard Zinman,Rury R. Holman,Steven M. Haffner,Daniel Levy,John M. Lachin,Rhona A. Berry,Heise Ma,Nigel P. Jones,Martin I. Freed +12 more
TL;DR: The goal was to evaluate the long-term efficacy of monotherapy with rosiglitazone on glycemic control and on the progression of pathophysiological abnormalities associated with type 2 diabetes as compared with metformin or glyburide monotherapy.
Journal ArticleDOI
Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes
Steven E. Kahn,Bernard Zinman,Steven M. Haffner,M. Colleen O’Neill,Barbara G. Kravitz,Dahong Yu,Martin I. Freed,William H. Herman,Rury R. Holman,Nigel P. Jones,John M. Lachin,Giancarlo Viberti +11 more
TL;DR: In recently diagnosed, drug-naive type 2 diabetic subjects, markers of inflammation and fibrinolysis are strongly related to the number of metabolic syndrome components, and this relationship is determined by body adiposity and not by insulin sensitivity or glucose control.
Journal ArticleDOI
Phenotypic Characteristics of GAD Antibody-Positive Recently Diagnosed Patients With Type 2 Diabetes in North America and Europe
TL;DR: In the GAD-positive individuals, the prevalence of the metabolic syndrome as defined by NCEP ATP III (National Cholesterol Education Program Adult Treatment Panel III) was also lower, and phenotypic differences may underlie a potential difference in the natural history of hyperglycemia and its clinical outcomes.
Journal ArticleDOI
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes
Bernard Zinman,Steven M. Haffner,William H. Herman,Rury R. Holman,John M. Lachin,Barbara G. Kravitz,Gitanjali Paul,Nigel P. Jones,R. Paul Aftring,Giancarlo Viberti,Steven E. Kahn +10 more
TL;DR: Commonly measured bone biomarkers suggest that changes in bone resorption may be partly responsible for the increased risk of fracture in women taking thiazolidinediones.